3T Biosciences
An immunotherapy company developing next-generation therapies for the treatment of solid tumors and other immune-mediated diseases.
Based in South San Francisco, 3T Biosciences was founded in 2017. 3T's proprietary 3T-TRACE platform facillitates target discovery and therapeutic development by taking advantage of diverse target libraries and machine-learning algorithms to identify and validate T cell receptor (TCR) targets and specificities.
Latest 3T Biosciences News & Features
4 January 2024
9 January 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze